3-Nitrotyrosine (NT) levels in serum and its association with insulin resistance in patients with type 2 diabetes mellitus: Biomarker role of NT in the assessment of oxidative stress mediated impending vascular complications in nephropathy
-
Published:2022-09-12
Issue:4
Volume:42
Page:693-698
-
ISSN:0970-2067
-
Container-title:Biomedicine
-
language:
-
Short-container-title:Biomedicine
Author:
Meka Farid Babu ,A.R. Srinivasan,Benerji G.V.
Abstract
Introduction and Aim: 3-Nitrotyrosine (NT) has been recognized as a marker of oxidative stress in diabetes mellitus. NT has also been studied in diverse metabolic conditions. The aim of our study was oriented towards the role of NT as a predictor of oxidative stress mediated impending nephropathy in diabetes mellitus and that with reference to albuminuria.
Materials and Methods: A total of 150 type 2 diabetics in the age group 35 - 50 years were enrolled as three groups, comprising 50 each, based on albuminuria. 50 healthy age and gender matched subjects constituted the control group. Serum NT and Insulin were assessed by ELISA. HbA1c was quantitated by immunoturbidimetric method and microalbumin was assessed by turbilatex method. Routine biochemistry was enabled through ERBA EM-200 fully automated analyzer. Stringent quality control was affected. The study was begun following approval accorded by the competent committees.
Results: NT levels were positively correlated with albumin-creatinine ratio and insulin resistance. NT could be used as a predictor of impending vascular complications in diabetic nephropathy.
Conclusion: NT levels could act as a predictor of oxidative stress mediated diabetic nephropathy in the light of albuminuria.
Publisher
Indian Association of Biomedical Scientists
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference28 articles.
1. Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137-149. 2. Garber, A.J., Handelsman, Y., Einhorn, D., Bergman, D.A., Bloomgarden, Z.T., Fonseca,V., et al., Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933-946. 3. Levey, A.S., de Jong, P.E., Coresh, J., El Nahas, M., Astor, B.C., Matsushita, K., et al., The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17-28. 4. Eboh, C., Tahseen, A. Chowdhury. Management of diabetic renal disease. Ann Transl Med. 2015; 3(11): 154:1-8 5. Perkins, B.A., Ficociello,.L.H, Ostrander, B.E., Silva,K.H., Weinberg, J., Warram, J.H., et al., Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007; 18(4):1353-1361.
|
|